+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Coronavirus Disease 2019 (COVID-19) Impact on the Sales of Immunology Drugs

  • ID: 5264131
  • Report
  • January 2021
  • Region: Global
  • 46 pages
  • GlobalData
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • AbbVie
  • Amgen
  • Eli Lilly
  • Johnson & Johnson
  • Pfizer
  • Roche
  • MORE
Summary

The global spread of SARS-CoV-2, the virus that causes coronavirus disease 2019 (COVID-19), throughout 2020 has led to widespread disruption of daily life, leading to national lockdowns in attempts to mitigate the pandemic. Disruptions to healthcare systems and the management of chronic diseases has resulted in patients having difficulty seeing HCPs and receiving treatment, including for autoimmune and inflammatory conditions, especially as many of these immunological disorders require ongoing therapy.

Immunological disorders whose treatment has been disrupted include psoriasis, rheumatoid arthritis, inflammatory bowel disease, and others. The key objectives of this report are to: assess the impact of the COVID-19 pandemic on dermatology, gastroenterology, and rheumatology practices; understand how the immunology landscape has changed as a result of the pandemic, and whether these changes are permanent; quantify the impact of the pandemic on sales of key players in the immunology sector; determine how quickly key players will financially recover from the pandemic.

Key Highlights
  • Assess the impact of the COVID-19 pandemic on dermatology, gastroenterology, and rheumatology practices.
  • Understand how the immunology landscape has changed as a result of the pandemic, and whether these changes are permanent.
  • Quantify the impact of the pandemic on sales of key players in the immunology sector.
  • Determine how quickly key players will financially recover from the pandemic.
Scope
  • How patient appointments are conducted.
  • How treatment selection and administration has been affected.
  • Whether subsequent waves of infection are expected.
  • How the sales of key immunology drugs have been affected.
Reasons to Buy

The report will enable you to -
  • Develop business strategies by understanding the trends shaping and driving the immunology market in the US and 5EU.
  • Drive revenues by understanding the key trends and how companies are reacting during the pandemic in the US and 5EU immunology market.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.
  • Create effective strategies to counter disruption caused by the pandemic in order to gain a competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • AbbVie
  • Amgen
  • Eli Lilly
  • Johnson & Johnson
  • Pfizer
  • Roche
  • MORE
  • Key Findings
  • Background & Methodology
  • Impact of COVID-19 on Patient Appointments
  • History of Immunology Drugs in Treating COVID-19 Infection
  • Impact of COVID-19 on Prescription Habits
  • Expectation for a Subsequent Wave
  • Impact of COVID-19 on Immunology Drug Sales
  • Appendix
  • Contact the Publisher
Note: Product cover images may vary from those shown
3 of 3
  • AbbVie
  • Almirall
  • Amgen
  • Bausch Health
  • Eli Lilly
  • Janssen
  • Johnson & Johnson
  • Novartis
  • Pfizer
  • Regeneron
  • Roche
  • Sanofi
  • Takeda
  • UCB
Note: Product cover images may vary from those shown
Adroll
adroll